Favipiravir
Cost Effective Process Technology of Favipiravir Developed by CSIR Used by M/s Cipla Ltd.
Glenmark Announces Results of Phase 3 Clinical Trial of Favipiravir on COVID Patients
Glenmark’s Favipiravir is Different from Livealth Bio Pharma’s Livfavir
COVID-19 Drug By Glenmark Set for Market at Rs 103 Per Tablet After Getting DCGI Approval
Glenmark: Antiviral Favipiravir To Enter into Phase 3 of Clinical Trials
/smstreet/media/agency_attachments/3LWGA69AjH55EG7xRGSA.png)
/smstreet/media/post_banners/sSwHfZrtHNlYUDmoCizz.jpg)
/smstreet/media/post_banners/ll0X7b2qDwVeKjiVREVN.jpg)
/smstreet/media/post_banners/RsBrNSckDwizvYFUlXTP.jpeg)
/smstreet/media/post_banners/BtMqFPKcDwTyO19RusaX.jpg)
/smstreet/media/post_banners/w1225RSqGUfDYgavyIMk.png)
/smstreet/media/post_banners/HIrTI7VHY7cpyDkakHG3.jpg)
/smstreet/media/post_banners/6jRvHR3rt9GM6YI6Gh47.jpg)
/smstreet/media/post_banners/9zf8tBMgsOhX2Ok2nXi4.jpg)
/smstreet/media/post_banners/5IRtH3ivDgqLzubnqIXd.jpg)
